The Beryl Institute announces the publication of Volume 7, Issue 1 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices around understanding and improving patient experience.

NASHVILLE, Tenn. (PRWEB)
April 29, 2020

The Beryl Institute announces the publication of Volume 7, Issue 1 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices around understanding and improving patient experience. Read in over 200 countries and territories, PXJ has almost 600,000 article downloads and is committed to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation on patient experience.

Published in association with The Beryl Institute, Volume 7, Issue 1 includes 16 articles from 47 contributing authors representing commentaries, personal narratives, research studies and case studies and covers a selection of topics such as:

• The essential nature of experience in a time of crisis and beyond
• Paying it forward: A cancer survivor and his wife share their reflections and recommendations as a patient and caregiver
• Measuring patient-centered care for specific populations: A necessity for improvement
• Patient feedback: Listening and responding to patient voices
• Using shared mental models to conceptualize patients as professionals, decision-makers, collaborators, and members of interprofessional healthcare teams
• Exploring perceptions and experiences of client and family-centred care through photovoice
• Is there a correlation between the patient-doctor relationship questionnaire and other patient-reported experience measures?
• Finding common threads: How patients, physicians and nurses perceive the patient gown
• Patient education in the hospital-at-home care context

Submissions represent a broad range of global organizations and institutions including University of Pennsylvania, Australian Institute of Health Service Management, VHA Home HealthCare, Dell Medical School – The University of Texas at Austin, Penn State College of Medicine, Åbo Akademi University, Mount Sinai Health System, Northwell Health, Zucker School of Medicine at Hofstra, Yale New Haven Hospital, San Jose State University, University of Nebraska Medical Center, and more.

“As we launch our 7th volume, we find ourselves in a time of crisis that calls on the best of our humanity. This is not a reality we could have imagined, yet it is one – as revealed in all the work of those who have contributed to the pages of PXJ over our first 6 years – we have been prepared for all along.” said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute. “And while we can all say we are never truly ready for a crisis of this proportion or impact, the collective spirit and commitment we have built together, and represented on the pages of this issue, will guide us forward in the days to come.”

To access Volume 7, Issue 1 of PXJ, visit: http://pxjournal.org/journal/

PXJ publishes twice annually in April and November. Submissions are accepted on an ongoing basis and should follow the requested submission types and adhere to author guidelines. Papers should address the full range of topics critical to the evaluation and impact of patient experience practices, efforts and influences.

PXJ is also accepting submissions for the 2020 Special Issue to address sustaining a focus on human experience in the face of COVID-19. The deadline for submissions for that issue is June 1, 2020. Learn more: https://bit.ly/2W74BDL

###

About Patient Experience Journal:

Patient Experience Journal (PXJ) is a peer-reviewed, open-access journal published in association with The Beryl Institute. Read in over 200 countries and territories, PXJ is committed to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation on patient experience.

About The Beryl Institute:

The Beryl Institute is a global community that builds the capacity of organizations to elevate the human experience in healthcare and develops individuals who impact experience excellence. We believe human experience is grounded in experiences of patients & families, those who work in healthcare and the communities they serve.

We define the patient experience as the sum of all interactions, shaped by an organization’s culture, that influence patient perceptions across the continuum of care.

Share article on social media or email:

WCG FDAnews

FALLS CHURCH, Va. (PRWEB)
April 29, 2020

It’s no secret. Artificial intelligence (AI) and robotics process automation (RPA) help manufacturers develop quality products that are safe for patients.

What are the best ways to apply AI and RPA to one’s own quality management processes (QMS) for compliance purposes? Does one know if AI and RPS can support predictive decision- making and aid in risk management strategies?

Join Christy Mazzarisi, Quality Lead at CGI, and master the latest methods for applying AI and RPA to your QMS:

• 
  Determine how new technology such as AI and RPA decreases costs, frees up staff time for higher-value tasks and increases employee engagement
• Assess intelligent automation and how it reduces cost and increases quality and productivity
• Familiarize oneself the ways AI and RPA support capabilities for digital transformation and implementation approaches
• Gain a better understanding of what to look for within your QMS to ensure it is capturing continuous improvement initiatives such as processes and systems
• Critically evaluate what continuous improvement really means and how to apply it for inspection purposes

Use AI and RPA to improve one’s everyday production activities to ensure quality and compliance.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

Continuous Quality Improvement for Pharmaceutical and

Medical Device Manufacturers:

Using Artificial Intelligence and Robotics Process Automation

An FDAnews Webinar

Wednesday, May 13, 2020 • 1:30-3:00 p.m. EDT

https://www.fdanews.com/continuousqualityimprovement

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/continuousqualityimprovement

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations

Share article on social media or email:

By bringing together individuals, institutions, organizations and the systems’ developers, we’re able to create an intellectually, scientifically and technologically rich environment for collaboration.

SAN JOSE, Calif. (PRWEB)
April 29, 2020

The Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science and clinical practice of radiosurgery, today announced that NYU Langone Hospitals and The University of Texas MD Anderson Cancer Center have joined the organization’s growing membership in its RSS Sponsorship Alliance, along with the Hermitage Medical Clinic in Dublin, Ireland, marking the first international medical center to join the alliance.

As the professional organization for industry standards, scientific methods and clinical advancements in stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), the RSS welcomes sponsoring organizations as partners. The RSS Sponsorship Alliance champions the evolution of science and research clinical practices, patient safety and efficacy, technological innovations and global adoption of SRS/SBRT techniques. Sponsors join the ranks of highly respected institutions, organizations, societies and corporations to support successful advancements in the field.

“By bringing together individuals, institutions, organizations and the systems’ developers, we’re able to create an intellectually, scientifically and technologically rich environment for collaboration. We firmly believe active collaboration is critical to advance the treatment techniques, patient care, safety standards, and the exchange of innovative ideas and experience,” said Kristine Gagliardi, RSS Founding Partner and Head of Strategic Development and Business Relations.

Through the RSS Sponsorship Alliance these members receive opportunities for collaboration and research through participation in the RSSearch® Patient Registry and Clinical Research Committee, along with access to educational resources and online communities. The RSS offers opportunities for Continuing Education for their institution, such as live and recorded webinars, clinical/advisory committees, RSS Residents Program and mentoring opportunities.

“Perlmutter Cancer Center at NYU Langone Health was an early adopter of SBRT, recognizing the important role it could play in improving patient care and helping to pave the way for its broader adoption. We are proud to become a member of the RSS Sponsorship Alliance and look forward to additional opportunities to collaborate, share knowledge and information, and advance the science and practice of SRS and SBRT,” said Alec Kimmelman, MD, PhD., Anita and Joseph Steckler Professor and Chair Department of Radiation Oncology, Perlmutter Cancer Center and Jonathan A. Haas, M.D., Chairman, Perlmutter Cancer Center Radiation Oncology at NYU Winthrop Hospital and Associate Professor of Radiation Oncology at NYU Long Island School of Medicine.

“For nearly 80 years, MD Anderson has worked to eliminate cancer by pioneering medical advances and remaining at the forefront of innovative therapies, so we are pleased to join the RSS Sponsorship Alliance to continue supporting the advancement of SRS and SBRT as critical elements of cutting-edge cancer care,” said Albert Koong, M.D., Division Head and Department Chair, Radiation Oncology at MD Anderson.

“On behalf of Hermitage Medical Clinic, we are very excited to become the first internationally based Medical Center Sponsor of the RSS. This partnership allows us access into a wide body of international experts in the field of SRS where potentially difficult cases can be discussed prior to treatment. We are keen to contribute to the RSSearch® Patient Registry and collaborate with others to facilitate research papers specific to SRS. The RSS partnership provides us the best possible access to experts in the field of SRS/SBRT,” said Daniel Rawluk, M.D.

Current Academic/Medical Center sponsors include Geisinger, Henry Ford Health System, Hematology-Oncology Associates of CNY, Montefiore Albert Einstein College of Medicine, Stanford Health Care, UAB Medicine, UPMC Hillman Cancer Center and UW Medicine.

As a member of the RSS Sponsorship Alliance, corporations and device manufacturers in addition to receiving world-wide exposure, gain access to a plethora of educational opportunities including SRS/SBRT focused white papers, clinical research program meeting participation, online continuing education programs, and technology/company specific webinars hosted by the RSS.

The RSS Sponsorship Alliance features three types of sponsors – Academic/Medical Center, Corporate/Manufacturer and Network Affiliates – with benefits tailored to each. Current corporate and network sponsors include Accuray, Elekta, Masep, Varian, ViewRay and Zap Surgical Systems. PetCure Oncology is the RSS’s inaugural Network Affiliate sponsor.

More information on the RSS Sponsorship Alliance and its associated benefits can be found at https://therss.org/workwithus. Organizations interested in joining the RSS as a Sponsorship Alliance member should contact sponsorship@therss.org.

About The Radiosurgery Society®

The Radiosurgery Society (RSS) – a non-profit, independent, multi-disciplinary organization of surgeons, radiation oncologists, physicists, and allied professionals, who are dedicated to advancing the science and clinical practice of radiosurgery. Originally formed in 2002 and becoming (501c6) in 2008, the Radiosurgery Society today (http://www.therss.org) represents approximately 600 members who perform stereotactic body radiotherapy and radiosurgery in hospitals and freestanding centers throughout the world.

Share article on social media or email:

PriorityQ by Picis

“The benefit to healthcare providers is PriorityQ goes beyond a patient prioritization score. The real value of the solution is that it uses the “score” in conjunction with the hospital’s particular parameters to generate a forward looking schedule.” -Marcus Perez, EVP

WAKEFIELD, Mass. (PRWEB)
April 29, 2020

Picis announces the release of PriorityQ, a web-based solution designed to assist healthcare providers in managing surgical backlogs and waitlists through proactive prioritization planning.

As a result of the current global pandemic, clinicians have been forced to suspend non-urgent, elective procedures to protect resources to combat the surge of life-threatening COVID-19 cases.

Marcus Perez, Executive Vice President of Picis states, “As existing surgical backlogs continue to grow exponentially and facilities begin to resume elective surgeries, a daily process of meeting as a committee to manually review a triage list of patients is simply not scalable or efficient when so many patients are in need of care.”

As experts in surgical scheduling, Picis introduces PriorityQ to help administrators coordinate the surgical schedule based on aggregated data. Incorporating hospital thresholds, patient severity level, OR time and resources, PriorityQ collects multiple data points to determine a patient “score” and delivers a priority of surgical procedures over the coming weeks and/or months. For organizations that already have a prioritization scoring system, PriorityQ will import this information and include it in the factored results. This information empowers administrators with the ability to plan how to manage the queue, separate surgeries by service, while producing financials to show potential revenue generated based on the suggested schedule.

“The benefit to healthcare providers is PriorityQ goes beyond a patient prioritization score. The real value of the solution is that it uses the “score” in conjunction with the hospital’s particular parameters to generate a forward looking schedule. Simply put, it’s load planning. The key is providing each facility the flexibility to modify the schedule once scores are delivered and the ability to plan in advance how to manage the queue.” said Perez.

PriorityQ will be ready for implementation the week of May 4, 2020. To learn more, visit our website http://www.picis.com.

ABOUT PICIS:

Picis Clinical Solutions (Picis) is a global provider of clinical information solutions that automate the entire perioperative experience with one contiguous patient record, from preop to intraop and anesthesia through PACU. Picis continues to focus and specialize the integrated suite of solutions in life-critical areas of the hospital where the patients are the most vulnerable, the care process is the most complex, and an increasing majority of hospital costs and potential revenue are concentrated. The software enables rapid, sustained delivery of clinical documentation, and financial and operational results. From department performance to patient case costing, hospitals benefit from the ability to interact with the data needed to help clinicians improve patient care, engagement and hospital revenue goals. Picis Clinical Solutions, a wholly owned subsidiary of N. Harris Computer Corporation, is headquartered in Wakefield, Massachusetts with licensed systems for use at more than 400 hospitals worldwide.

Share article on social media or email:

Cisive Launches SAFE19 COVID-19 Clearinghouse to Help the World Safely Re-Open from Pandemic

We are thrilled about the release of SAFE19 because it is a solution that will help governments, businesses, and other organizations across the globe work collectively to reduce the impact of COVID-19.

HOLTSVILLE, N.Y. (PRWEB)
April 29, 2020

Cisive, a global provider of compliance-driven human capital management and risk management solutions, announces the release of its new SAFE19 COVID-19 Clearinghouse product, developed to address the world’s journey to re-open after the Coronavirus global pandemic. Cisive’s SAFE19 solution is a secure, paperless, central repository specifically designed to handle the uploading, validation, and compliance reporting on COVID-19 test and immunization data. With SAFE19, governments, businesses, and education institutions can safely re-open while controlling the spread of COVID-19.

SAFE19 is a flexible, data-driven solution designed to mitigate the risk of COVID-19 with the capability to evolve as vaccines and various testing options become available. The system has the capability to use an individual’s profile data and immunization status to generate a digital or physical badge to verify their immunity before allowing them to return to campus or work.

SAFE19 protects public health data and eliminates privacy concerns by offering a solution that is federal Fair Credit Reporting Act (FCRA) and Health Insurance Portability and Accountability Act (HIPAA) compliant. Designed to provide peace of mind to both organizations and end-users, SAFE19 provides confirmation authenticity of testing with dispute resolution to ensure the validity of individual records.

“Cisive is honored to contribute our solution to assist our global communities in recovering from the COVID-19 pandemic,” said James Owens, President and CEO at Cisive. “Our team collaborated to develop our new SAFE19 solution, which was specifically designed to help re-open communities in a safe and secure manner while controlling the spread of the Coronavirus. We are thrilled about the release of SAFE19 because it is a solution that will help governments, businesses, and other organizations across the globe work collectively to reduce the impact of COVID-19.”

SAFE19 is Cisive’s technology-enabled, full-service solution that offers governments, businesses, and education institutions with an option to safely re-open as the world enters the next phase of the COVID-19 pandemic. For more information about SAFE19 and other Cisive solutions, visit http://www.Cisive.com.

About Cisive

Cisive is a global leader in compliance-driven human capital and risk management solutions, providing onboarding and pre-employment background screening solutions to address the complex challenges and needs of large enterprises with dedicated, in-country account management teams committed to customer satisfaction. Cisive is accredited by the Professional Background Screeners Association (PBSA) and was named for the third consecutive year by HRO Today to the 2019 Baker’s Dozen Customer Satisfaction rankings of Top Pre-Employment Screening Providers, in addition to being named Company of the Year by CIO Review. The company and its brands serve clients in financial services, transportation, telecom/media, healthcare, utilities and the home services end-markets, among others. For additional information, please visit http://www.cisive.com.

Share article on social media or email:

“This designation recognizes Dr. Jay Page as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
April 29, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Jay Page, M.D., Arizona Institute of Urology in Tucson, AZ, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Page has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Jay Page as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email: